SYDNEY, March 28, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech company developing ...
MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug de...
* Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical t...
* Dr. Geoff Nichol, M.B., Ch.B., M.B.A., joins HaemaLogiX's Board of Directors as Non-Executive D...
* New Board appointment deepens and consolidates Servatus' extensive commercial and scientific ex...
SYDNEY, March 28, 2022 /PRNewswire/ -- Sydney-based boutique investor and public relations consulta...
* Study to look at the link between the gut microbiome and sleep, by treating patients who suffer...
* Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma d...
Highlights: * XPON Technologies set to trade on the ASX today from 12.00 PM AEDT * Oversubscrib...
* QBiotics commences the Australian commercial launch of its lead veterinary drug, STELFONTA®, wh...
SYDNEY, Dec. 2, 2021 /PRNewswire/ -- EZZ Life Science Holdings Limited (ASX: EZZ), a genomic life s...
SYDNEY, Nov. 23, 2021 /PRNewswire/ -- EZZ Life Science Holdings Limited (ASX: EZZ),an Australian ge...
* Race Oncology's drug Zantrene shown to protect human heart muscle cells from anthracycline-indu...
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- From November 5 to 10, the 4th China International ImportExpo...
SYDNEY, Nov. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncolo...
About EZZ Life Science Holdings EZZ Life Science Holding Limited (ASX:EZZ) is a genomic life scien...
MELBOURNE, Australia, Oct. 20, 2021 /PRNewswire/ -- Australian mid-clinical stage antiviral drug de...
SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncolo...
* Zantrene® at low concentrations kills high FTO producing melanoma cancer cells * Sensitivity ...
SYDNEY, Sept. 30, 2021 /PRNewswire/ -- EZZ Life Science Holdings Limited (ASX: EZZ),a producer of c...
